ReviewJournal of bioenergetics and biomembranes1997
Treatment of mitochondrial disease.
Review in Journal of bioenergetics and biomembranes, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- An acetate prodrug of a pyridinol-based vitamin E analogue.Pharmaceutical research · 2011Article
- Clinical practice: heart failure in children. Part II: current maintenance therapy and new therapeutic approaches.European journal of pediatrics · 2010Review
- Neonatal mitochondrial encephaloneuromyopathy due to a defect of mitochondrial protein synthesis.Journal of the neurological sciences · 2008Article
- Linked oligodeoxynucleotides show binding cooperativity and can selectively impair replication of deleted mitochondrial DNA templates.Nucleic acids research · 2001Article
- Mitochondrial toxicity and HIV therapy.Sexually transmitted infections · 2001Review
- Targeting peptide nucleic acid (PNA) oligomers to mitochondria within cells by conjugation to lipophilic cations: implications for mitochondrial DNA replication, expression and disease.Nucleic acids research · 2001Article
- Mitochondrial Disease.Current treatment options in neurology · 2001Article
- Toxicity of antiretroviral nucleoside and nucleotide analogues: is mitochondrial toxicity the only mechanism?Drug safety · 2000Review
- Peptide nucleic acid delivery to human mitochondria.Gene therapy · 1999Article
- Clinical mitochondrial genetics.Journal of medical genetics · 1999Review
- SCID mice containing muscle with human mitochondrial DNA mutations. An animal model for mitochondrial DNA defects.The Journal of clinical investigation · 1998Article
- Biochemical monitoring of the treatment in paediatric patients with mitochondrial disease.Journal of inherited metabolic disease · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Defects of the mitochondrial genome are widely recognized as important causes of disease in man. Patients may present at any age with clinical symptoms that vary from acute episodes of lactic acidosis in infancy to severe neurodegenerative illness in adulthood. While modern molecular genetic techniques have facilitated major advances in the diagnosis and characterization of specific molecular defects, treatment for the majority of patients remains supportive in the absence of definitive biochemical therapies. As a consequence, the possibilities for mitochondrial DNA gene therapy must be considered. In this review, we will evaluate the current biochemical strategies available to clinicians for the management of patients with mitochondrial disease and examine the possible approaches to the gene therapy of mitochondrial DNA defects.
Indexed as
Identifiers
9239544What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.